JP5734856B2 - 癌及び線維症疾患の治療に使用される医薬及び組成物ならびにその使用 - Google Patents

癌及び線維症疾患の治療に使用される医薬及び組成物ならびにその使用 Download PDF

Info

Publication number
JP5734856B2
JP5734856B2 JP2011530354A JP2011530354A JP5734856B2 JP 5734856 B2 JP5734856 B2 JP 5734856B2 JP 2011530354 A JP2011530354 A JP 2011530354A JP 2011530354 A JP2011530354 A JP 2011530354A JP 5734856 B2 JP5734856 B2 JP 5734856B2
Authority
JP
Japan
Prior art keywords
peptide
pharmaceutical composition
cancer
liver
pdgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011530354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504941A5 (enExample
JP2012504941A (ja
Inventor
ファン、ラン
ジョウ、ファ
ユアン、シェンタオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2012504941A publication Critical patent/JP2012504941A/ja
Publication of JP2012504941A5 publication Critical patent/JP2012504941A5/ja
Application granted granted Critical
Publication of JP5734856B2 publication Critical patent/JP5734856B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2011530354A 2008-10-09 2009-09-21 癌及び線維症疾患の治療に使用される医薬及び組成物ならびにその使用 Expired - Fee Related JP5734856B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2008102009378A CN101392026B (zh) 2008-10-09 2008-10-09 用于预防和治疗纤维化类疾病以及肝癌的多肽
CN200810200937.8 2008-10-09
PCT/CN2009/074048 WO2010040305A1 (en) 2008-10-09 2009-09-21 Pharmaceutical being used for treating cancer and fibrosis disease and the composition and uses thereof

Publications (3)

Publication Number Publication Date
JP2012504941A JP2012504941A (ja) 2012-03-01
JP2012504941A5 JP2012504941A5 (enExample) 2012-11-08
JP5734856B2 true JP5734856B2 (ja) 2015-06-17

Family

ID=40492557

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011530354A Expired - Fee Related JP5734856B2 (ja) 2008-10-09 2009-09-21 癌及び線維症疾患の治療に使用される医薬及び組成物ならびにその使用

Country Status (5)

Country Link
US (1) US8637467B2 (enExample)
EP (1) EP2344528B1 (enExample)
JP (1) JP5734856B2 (enExample)
CN (1) CN101392026B (enExample)
WO (1) WO2010040305A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101392026B (zh) * 2008-10-09 2011-11-09 黄岚 用于预防和治疗纤维化类疾病以及肝癌的多肽
CN111701020A (zh) * 2020-06-08 2020-09-25 南通大学 一种治疗pdgf诱导的肝纤维化的分子靶点
CN120536440A (zh) * 2025-05-23 2025-08-26 中山大学中山眼科中心 一种靶向pdgf-c抑制纤维化的核酸适配子及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US20030211994A1 (en) * 1998-09-30 2003-11-13 Ludwig Institute For Cancer Research Composition and method for modulating vasculogenesis or angiogenesis
CA2344561A1 (en) * 1998-09-30 2000-04-06 Ludwig Institute For Cancer Research Platelet-derived growth factor c, dna coding therefor, and uses thereof
IL143832A0 (en) 1998-12-22 2002-04-21 Janssen Pharmaceutica Nv Vascular endothelial growth factor-x
CN1355209A (zh) * 2000-11-24 2002-06-26 复旦大学 一种新的多肽——钙依赖性氯离子通道16.72和编码这种多肽的多核苷酸
EP1513870A4 (en) * 2002-05-31 2006-06-07 Childrens Hosp Medical Center CFTR MODIFIER GENES AND EXPRESSED POLYPEPTIDES SUITABLE FOR THE TREATMENT OF CYSTIC FIBROSIS AND METHOD AND PRODUCTS FOR DETECTING AND / OR IDENTIFYING THEM
AU2004209668A1 (en) 2003-02-04 2004-08-19 Flanders Interuniversity Institute For Biotechnology VEGF-B and PDGF modulation of stem cells
ES2363758T3 (es) 2005-08-15 2011-08-16 Vegenics Pty Ltd Vegf y pdgf modificados con propiedades angiogénicas mejoradas.
CN101392026B (zh) 2008-10-09 2011-11-09 黄岚 用于预防和治疗纤维化类疾病以及肝癌的多肽

Also Published As

Publication number Publication date
EP2344528A1 (en) 2011-07-20
CN101392026A (zh) 2009-03-25
US8637467B2 (en) 2014-01-28
WO2010040305A1 (en) 2010-04-15
CN101392026B (zh) 2011-11-09
EP2344528B1 (en) 2013-12-18
US20110263513A1 (en) 2011-10-27
JP2012504941A (ja) 2012-03-01
EP2344528A4 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
ES2281704T3 (es) Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasicas.
JP6420459B2 (ja) 線維症抑制活性を有するペプチド及びこれを含む組成物
EP1833504A2 (en) Sustained delivery of pdgf using self-assembling peptide nanofibers
JP2022090049A (ja) Ｎｐｒａアゴニスト、組成物およびその使用
WO2011119009A2 (en) Peptides for promoting angiogenesis and an use thereof
US20090036369A1 (en) Anti-tumor agents comprising r-spondins
JP2022544481A (ja) ポリペプチドまたはその誘導体の応用
BR112021008797A2 (pt) Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame
CN107629114B (zh) 多肽、其衍生物及其在制备抗肺纤维化的药物中的应用
EP3059243B1 (en) Yap protein inhibiting polypeptide and application thereof
JP2023053978A (ja) 環状プロサポシンペプチドおよびその使用
JP2012504941A (ja) 癌及び線維症疾患の治療に使用される医薬及び組成物ならびにその使用
ES2330918T3 (es) Inhibidor del activador del factor de crecimiento de hepatocitos para usar en la modulacion de la angiogenesis y la cardiovascularizacion.
WO2010141946A1 (en) Peptide-coated cell localization to diseased or damaged tissues and methods related thereto
EP2552940A2 (en) Peptides for promoting angiogenesis and an use thereof
CA2494542A1 (en) Preventing secondary lymphedema with vegf-d dna
JP4094814B2 (ja) 血管新生抑制剤
CN107446024B (zh) 一种可拮抗ddx3蛋白rna结合活性的多肽dip-13及其应用
JPWO1999055361A1 (ja) 血管新生抑制剤
KR102216566B1 (ko) 종양 혈관형성을 억제하는 vegf 딥 블로커를 포함하는 암 치료용 조성물 및 이의 제조방법
WO2013166944A1 (zh) 一种rtn4b相关多肽及其制备与应用
CN101017166A (zh) 人rtn4b蛋白在制备抗肿瘤药物中的应用
KR20130060846A (ko) 암세포 특이적 세포괴사 유도 및 암 소멸 효과를 나타내는 세포사 유도 융합 펩타이드
CN109734779B (zh) 一种靶向Tie-1的多肽及其应用
Tesoro et al. TITTLE: Cardioprotective Effect of New NIL10 Nanoparticles Through IL10 Receptor/STAT3 Activation in Mice and Pigs Subjected Acute Myocardial Infarction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150415

R150 Certificate of patent or registration of utility model

Ref document number: 5734856

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees